Related Experiment Video
Updated: Feb 8, 2026
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy
Srikanth Yandrapalli1, Mohammed Hasan Khan2, Yogita Rochlani2
1Department of Internal Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY, USA.
Insights
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), offers significant cardiovascular benefits. This therapy shows promise for heart failure patients and potentially other cardiovascular conditions.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Science
Background:
- Cardiovascular disease remains a leading cause of death globally.
- Existing treatments for heart failure show limitations in sustained efficacy.
- There is a need for novel therapies to address the growing cardiovascular health burden.
Purpose of the Study:
- To evaluate the efficacy of sacubitril/valsartan compared to standard care.
- To explore the tissue-level effects and broad clinical applications of this novel ARNI.
Main Methods:
- Clinical trials comparing sacubitril/valsartan with enalapril in heart failure with reduced ejection fraction.
- In-vitro and tissue-level investigations into the mechanisms of action.
- Observational studies and analyses across various cardiovascular disease phenotypes.
Main Results:
- Sacubitril/valsartan demonstrated substantial cardiovascular benefits over enalapril.
- Tissue-level studies revealed anti-remodeling and cardioprotective effects.
- Preliminary data suggest potential benefits in heart failure with preserved ejection fraction, hypertension, and post-myocardial infarction scenarios.
Conclusions:
- Sacubitril/valsartan represents a significant therapeutic advancement for cardiovascular disease.
- The ARNI offers a promising new treatment option for heart failure and potentially other CV conditions.
- Further research is warranted to fully elucidate its role across the spectrum of cardiovascular medicine.
Abstract:
Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction. Further investigations of this novel combination ARNI at the tissue level shed light into the anti-remodeling and cardioprotective effects of sacubitril/valsartan, while clinical studies in the phenotypes of HF with preserved ejection fraction, hypertension and subsets, coronary outcomes, postmyocardial infarction, and renal disease suggested that this combination could be beneficial across a wide spectrum of CV disease. Sacubitril/valsartan is a much-needed therapeutic advance in the avenue of CV disease.
Related Concept Videos
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
02:55The Evidence for Evolution
00:59Gene Therapy
01:14Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
01:27Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...